Apollo Endosurgery, Inc. announced that the company expects full year 2022 revenue between $73 million and $75 million, representing growth of approximately 16% to 19% over 2021. The Company continues to monitor the potential and uncertain impact of the ongoing COVID-19 pandemic. Should hospitals or outpatient centers, where the company's procedures are performed, experience continued or additional surges in cases, and need to defer elective procedures to preserve capacity for COVID-19 patients, the company's ability to achieve these financial projections could be adversely affected.
Apollo Endosurgery, Inc.
Equities
APEN
US03767D1081
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
+75.69% | 12.57B | |
-25.53% | 7.26B | |
+14.60% | 5.47B | |
-20.93% | 4.62B | |
+14.51% | 4.08B | |
-23.55% | 3.76B | |
-33.41% | 2.51B | |
+29.94% | 2.09B | |
+0.37% | 2.04B |